The phase 2 study tested four doses of the glucagon-like peptide-1 receptor agonist among 626 participants, Pfizer said in a Dec. 1 news release.
After taking the pill twice a week for eight months, participants lost between 8% and 13% of their weight compared to the placebo. Among those who received the drug for 26 weeks, reductions in body weight ranged from 5% to 9.5%.
The most common side effects were nausea (with 73% reporting the adverse event), vomiting (47%) and diarrhea (25%). Pfizer said most adverse events were mild, and no serious safety risks were found. The discontinuation rates for the drug were higher than 50%, while the placebo’s discontinuation rate was about 40%.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
